CRISPR licensees hold tight as patent skirmishes play out

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

CRISPR licensees hold tight as patent skirmishes play out

With the patent wars continuing to rage at the IP offices between key patent owners, in-house counsel say they are waiting for the matter to sort itself out so they can progress with licensing deals



CRISPR skirmishes at the USPTO are fostering uncertainty in the gene-editing space and putting licensees on edge as they wait to see who will own what when the dust settles.


Last summer, the scuffle between the two largest CRISPR patent owners – the University of California Berkeley and the Broad Institute – was reignited when the USPTO posted documents declaring interference between their patents – meaning that they might cover overlapping IP.

A month later, biotech company Sigma-Aldrich filed an interference petition and added another player to the mix; although said petition was dismissed by the Patent Trial and Appeal Board in September.

And this month it was announced that UC Berkeley now has the largest CRISPR-Cas9 portfolio, after a five-week spate of patents for the gene-editing technology being awarded to the university by the USPTO.

In-house sources say they are hesitant to go ahead with licensing deals while these patent wars continue because licensing decisions must be informed by factors such as which entities own what, how broad certain technologies are and where the application overlaps are.

“It is always positive for the rest of the community in this space to know who owns what patents so we can go ahead with licensing decisions,” says the head of IP policy at a pharmaceutical company in the US. “Finality and clarity is needed in the long run.”

Limagrain head of IP Franck Coutand in France adds that the lack of clarity could delay the adoption of CRISPR technologies in agriculture as well because stakeholders will not want to take a licence until they find out where they need to get one.

“I’m not sure anyone knows who to pay at the moment,” he says. “Lots of people and companies don't have any problems getting licences for the things they need, but if they don’t know where to get good tools, that uncertainty leads to speculation.

“It forces them to wait and see who the owner will be. It is difficult to know precisely when the dust will settle.”

He adds that agricultural players, and perhaps human therapeutics players too, do not want to have to pay twice for the same rights.

Laurie Hill, vice president of IP at Genentech in California, says that most therapeutic players are similarly waiting to see how and when the matter will sort itself out.

Sources noted in an article published by Patent Strategy last February that the lack of clarity surrounding who owns which patents is a key reason why a CRISPR patent pool is unlikely to emerge any time soon.

CRISPR – which stands for clustered regularly interspaced short palindromic – was first identified as a cheap, effective and usable gene-editing tool in 2012. That discovery led to a patent boom in 2013 and an increasing number of year-on-year applications.

Innovation momentum

Despite the uncertainty surrounding CRISPR patents, in-house sources are confident that innovation will continue.

For those players in the human therapeutics and agricultural industries that have already taken a licence, it should not be too difficult to change those arrangements as the CRISPR-Cas9 patent ecosystem alters.

“We’re not hugely worried about whoever comes out with which patents,” says the US pharmaceuticals head of IP policy. “If we have to make changes to licensing arrangements, as you always do when IP changes hands, then we will.

“I cannot comment on what licences we have, of course, but to the extent that we have licences that are impacted by these patent office skirmishes, those changes will not fundamentally disrupt work in the CRISPR space.”

Sources add that while the patents owned by UC Berkeley and the Broad Institute are important patents because they are early rights surrounding the gene-editing technology, they are not the only CRISPR-Cas9 patents out there. Other smaller players, including Duke University, have IP that is not affected by the patent office wars.

Furthermore, some businesses are exploring other forms of CRISPR beyond Cas9, including Cas12, in an effort to find an even better gene-editing tool that falls outside the UC Berkeley and the Broad’s reach.

As such, innovation in this space is likely to continue. The US pharma head of IP policy points out that organisations are interested in advancing CRISPR technologies, and that so long as the impetus is there, these skirmishes at the patent offices are very unlikely to completely derail efforts.

more from across site and SHARED ros bottom lb

More from across our site

The IP services provider is targeting further expansion as cost and efficiency pressures push law firms and in-house teams to rethink how they manage global portfolios
Two experienced UPC practitioners join the UK IP boutique’s growing German operation, with further recruitment planned as the firm expands in Europe
The Australian IP firm is taking on bigger rivals in Southeast Asia, betting that agility and transparent pricing can help it stand out
The firm has brought in former Weil IP leaders Doug Lumish and Jeff Homrig as it looks to deepen its patent, trade secrets and ITC bench
Bird & Bird helps GSK score a major injunction as the battle to become the UPC’s busiest division tightens, and overall filings reach a new monthly high
CEO Annette Bach explains how the Danish IP consultancy plans to build on its 65% profit growth while keeping external investment off the table for now
Belgian attorneys have revived fax systems to protect clients’ filing rights, while uncertainty over exposed patent data has left firms struggling to answer questions about the breach
In his first interview since leaving Weil Gotshal & Manges, Chris Henry explains why he returned to Latham and how he plans to bolster its tech disputes offering
As GTA VI underlines the extraordinary value of gaming franchises, lawyers at Clifford Chance say investors need to know the IP behind their next deal can deliver the growth they are paying for
As ‘big law’ invests in IP litigation, trial firms are emerging as a valuable source of seasoned courtroom talent
Gift this article